Nothing Special   »   [go: up one dir, main page]

DK1962886T4 - Stabile proteinformuleringer - Google Patents

Stabile proteinformuleringer Download PDF

Info

Publication number
DK1962886T4
DK1962886T4 DK06846683.8T DK06846683T DK1962886T4 DK 1962886 T4 DK1962886 T4 DK 1962886T4 DK 06846683 T DK06846683 T DK 06846683T DK 1962886 T4 DK1962886 T4 DK 1962886T4
Authority
DK
Denmark
Prior art keywords
protein formulations
stable protein
stable
formulations
protein
Prior art date
Application number
DK06846683.8T
Other languages
English (en)
Other versions
DK1962886T3 (da
Inventor
Manisha M Dali
Charles E Dahlheim
Sunita Borsadia
Vijay H Naringrekar
Rajesh B Gandhi
Manoj Nerurkar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1962886(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1962886T3 publication Critical patent/DK1962886T3/da
Publication of DK1962886T4 publication Critical patent/DK1962886T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK06846683.8T 2005-12-20 2006-12-19 Stabile proteinformuleringer DK1962886T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Publications (2)

Publication Number Publication Date
DK1962886T3 DK1962886T3 (da) 2014-01-13
DK1962886T4 true DK1962886T4 (da) 2022-05-02

Family

ID=38057529

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06846683.8T DK1962886T4 (da) 2005-12-20 2006-12-19 Stabile proteinformuleringer

Country Status (25)

Country Link
US (1) US8476239B2 (da)
EP (1) EP1962886B2 (da)
JP (2) JP5247467B2 (da)
KR (1) KR101378194B1 (da)
CN (3) CN101584858A (da)
AR (2) AR058567A1 (da)
AU (1) AU2006330593B2 (da)
BR (1) BRPI0622256A2 (da)
CA (1) CA2634547C (da)
CL (1) CL2010000816A1 (da)
DK (1) DK1962886T4 (da)
EA (1) EA014232B1 (da)
ES (1) ES2436616T5 (da)
HK (1) HK1114568A1 (da)
HR (1) HRP20131196T4 (da)
IL (1) IL192104A (da)
NO (1) NO347247B1 (da)
NZ (1) NZ569108A (da)
PE (1) PE20071063A1 (da)
PL (1) PL1962886T6 (da)
PT (1) PT1962886E (da)
RS (1) RS53127B2 (da)
SG (1) SG153832A1 (da)
TW (3) TW200738261A (da)
WO (1) WO2007076354A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597215A (en) 2005-12-20 2012-11-30 Bristol Myers Squibb Co Compositions and methods for producing a composition
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
ES2694000T3 (es) 2008-10-06 2018-12-17 3-D Matrix Ltd. Tapón de tejido
DK2445616T3 (da) * 2009-06-23 2018-06-06 Ge Healthcare Bio Sciences Ab Simulatorindretning
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
US20140147418A1 (en) * 2011-04-15 2014-05-29 The Us Of America, As Represented By The Secretary Department Of Health And Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
US9511103B2 (en) 2011-04-20 2016-12-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
CA2851087C (en) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
EP2768532A4 (en) * 2011-10-18 2015-03-11 Coherus Biosciences Inc FORMANTS OF STANOLPT STABILIZED WITH SODIUM CHLORIDE
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
JP2015522024A (ja) 2012-06-29 2015-08-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 糖タンパク質の凝集を低下させるための方法
CN104902974B (zh) 2012-07-06 2017-07-28 三维矩阵有限公司 肽溶液的灌装加工法
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
DK2890791T3 (da) 2012-08-31 2019-06-11 Us Health Aav-medieret aquaporingenoverførsel til behandling af sjögrens syndrom
SG10201705668XA (en) 2012-09-07 2017-08-30 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
PE20200607A1 (es) 2012-09-11 2020-03-10 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
WO2014149067A1 (en) * 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
EP3628337A1 (en) 2014-03-10 2020-04-01 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
MX2016011102A (es) 2014-03-19 2017-01-26 Bristol Myers Squibb Co Metodos para tratar rechazo al trasplante usando un anticuerpo de dominio dirigido contra cd40l.
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
JP2017513903A (ja) 2014-04-25 2017-06-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 早期ｒａを有する対象において薬剤フリー寛解を達成するためのｃｔｌａ４化合物の使用
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3157942B1 (en) 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MX2017004306A (es) 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
PE20180672A1 (es) 2015-05-29 2018-04-19 Agenus Inc Anticuerpos anti-ctla-4 y metodos de uso de los mismos
EP3347031B8 (en) * 2015-09-11 2021-04-28 Nutrition & Biosciences USA 1, LLC A composition comprising a protein and a polyalkoxy fatty compound
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
SG11201804758QA (en) * 2015-12-07 2018-07-30 Merck Patent Gmbh Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
CA3063730A1 (en) 2017-05-24 2018-11-29 Als Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
KR20200103733A (ko) 2017-12-22 2020-09-02 노파르티스 아게 Fgf21 변이체로 대사 장애를 치료하는 방법
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
AU2019274827A1 (en) * 2018-05-25 2021-01-07 Dr. Reddy's Laboratories Ltd. CTLA4-Ig fusion protein formulation
EP3801605A4 (en) * 2018-05-25 2022-03-16 Dr. Reddy's Laboratories Ltd. STABLE FUSION PROTEIN FORMULATION
US20210338586A1 (en) * 2018-06-26 2021-11-04 Lupin Limited Stable lyophilized dosage form of protein
CN110876269B (zh) * 2018-06-29 2021-07-30 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
KR20210121077A (ko) 2019-01-15 2021-10-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
JP7044822B2 (ja) 2019-09-09 2022-03-30 株式会社タクマ 燃焼制御システム、燃焼制御方法、情報処理装置、プログラムおよび記録媒体
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
US20240083970A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy’S Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
AU2022242009A1 (en) 2021-03-23 2023-10-12 King's College London Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
WO2024069420A2 (en) * 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197550T1 (de) * 1993-02-23 2000-12-15 Genentech Inc Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
NZ500539A (en) * 1995-07-27 2001-11-30 Genentech Inc An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU7317401A (en) 2000-07-03 2002-01-14 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1368059A1 (en) * 2001-01-26 2003-12-10 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
EP1450847B1 (en) * 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
SI1475101T1 (sl) 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
AU2003303394B2 (en) 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
KR20050088136A (ko) 2002-12-23 2005-09-01 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법
DK1610820T4 (da) * 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
MXPA06001225A (es) * 2003-08-04 2006-04-11 Bristol Myers Squibb Co Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1916997B1 (en) * 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe

Also Published As

Publication number Publication date
CN101378773B (zh) 2013-03-13
HK1114568A1 (en) 2008-11-07
US8476239B2 (en) 2013-07-02
BRPI0620186A2 (pt) 2010-07-06
PT1962886E (pt) 2014-01-07
NZ569108A (en) 2011-09-30
JP5247467B2 (ja) 2013-07-24
PE20071063A1 (es) 2007-10-24
AR058567A1 (es) 2008-02-13
RS53127B (en) 2014-06-30
TW201008595A (en) 2010-03-01
CN101378773A (zh) 2009-03-04
TWI393575B (zh) 2013-04-21
TW201008596A (en) 2010-03-01
AU2006330593B2 (en) 2012-07-26
BRPI0622256A2 (pt) 2011-08-09
JP5538309B2 (ja) 2014-07-02
NO347247B1 (no) 2023-07-31
IL192104A0 (en) 2008-12-29
TW200738261A (en) 2007-10-16
SG153832A1 (en) 2009-07-29
EA200801570A1 (ru) 2008-12-30
KR101378194B1 (ko) 2014-03-27
EA014232B1 (ru) 2010-10-29
ES2436616T5 (es) 2022-05-27
HRP20131196T4 (hr) 2022-06-10
KR20080078070A (ko) 2008-08-26
AU2006330593A1 (en) 2007-07-05
AR097561A2 (es) 2016-03-23
CN101822820A (zh) 2010-09-08
WO2007076354A3 (en) 2007-08-16
IL192104A (en) 2015-01-29
EP1962886A2 (en) 2008-09-03
EP1962886B2 (en) 2022-02-23
CA2634547C (en) 2016-10-11
HRP20131196T1 (en) 2014-01-31
ES2436616T3 (es) 2014-01-03
PL1962886T6 (pl) 2023-03-13
CL2010000816A1 (es) 2011-02-11
JP2011246470A (ja) 2011-12-08
NO20082628L (no) 2008-07-15
DK1962886T3 (da) 2014-01-13
RS53127B2 (sr) 2022-06-30
PL1962886T3 (pl) 2014-03-31
CA2634547A1 (en) 2007-07-05
JP2009524595A (ja) 2009-07-02
WO2007076354A2 (en) 2007-07-05
CN101584858A (zh) 2009-11-25
US20100166774A1 (en) 2010-07-01
EP1962886B1 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
DK1962886T4 (da) Stabile proteinformuleringer
NO20075628L (no) Farmasøytiske formuleringer
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP1951275A4 (en) COMPOSITION AGAINST ADIPOSITAS
DK1965646T3 (da) Herbicid sammensætning
DE502006006338D1 (de) Ächen
DK1928882T3 (da) (s)-n-methylnaltrexon
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
DE602006012066D1 (de) Daraus
EP1893244A4 (en) AGENTS FOR IMAGING
EP1875926A4 (en) Stable emulsion composition
DK1804871T3 (da) Forbedret mellemstykke
DE502006005207D1 (de) Bauteilen
DE602006006692D1 (de) Konzentrierte flüssige triazolfungizidformulierungen
ATE423466T1 (de) Herbizidzusammensetzung
DK1809660T3 (da) Thymus-specifikt protein
DE502006006589D1 (de) Teils
EP1750718A4 (en) FORMULATIONS OF ACYCLOVIR
DE602006007836D1 (de) Kontrastmittel
ITPD20050018A1 (it) Composizione insetticida
FR2894782B1 (fr) Implant capillaire
FI20055257A (fi) Luun proteiineja
FI20055258A0 (fi) Luun proteiineja
FI20055256A (fi) Luun proteiineja